Clinical Trials
65 trialsA Phase III Study of YL201 in Relapsed Small Cell Lung Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants.
Shanghai Allink Biotherapeutics Co., Ltd.
A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.
A Phase II Study of SKB571 in Patients With Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
SKB500 Combinations in Patients With Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1
Cancer Research UK
DEFLECT I
University Medical Center Groningen
CYTALUX Dose Extension Study
On Target Laboratories, LLC
Phase 3 Clinical Study of AK112 for NSCLC Patients
Akeso
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
Allist Pharmaceuticals, Inc.
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
Allist Pharmaceuticals, Inc.
Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC
Rutgers, The State University of New Jersey
MK-2870-003
Klus Pharma Inc.
SIM0610-101
Jiangsu Simcere Pharmaceutical Co., Ltd.
Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.
KZR-261 in Subjects With Advanced Solid Malignancies
Kezar Life Sciences, Inc.
JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.
A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer
Minghui Pharmaceutical (Hangzhou) Ltd
A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients
Ascentage Pharma Group Inc.
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.
First Affiliated Hospital of Zhejiang University
A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer
SUNHO(China)BioPharmaceutical CO., Ltd.
A Phase â…¡ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
RemeGen Co., Ltd.
Phase I Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd.
Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
Tongji Hospital
A Study of SYS6040 for Injection in Patients With Advanced Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd.
To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
AtezoMeso
Gruppo Oncologico Italiano di Ricerca Clinica
INJECTABL-1
Immunophotonics, Inc.
A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
Coherent Biopharma (Hefei) Co., Ltd.
Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations
BeBetter Med Inc
T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer
Tel Aviv Medical Center
VENEZO-LUNG
Instituto Oncológico Dr Rosell
ParaSOL
Guy's and St Thomas' NHS Foundation Trust
Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations
Liaoning Cancer Hospital & Institute
KEYNOTE F19
Evopoint Biosciences Inc.
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Eastern Cooperative Oncology Group
OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules
On Target Laboratories, LLC
Elucidate
On Target Laboratories, LLC
Study of Polymeric Micellar Paclitaxel, Platinum Combined With Sindilizumab Injection for Advanced Non-squamous NSCLC
Jiangsu Cancer Institute & Hospital
95% Effective Dose(ED95) of Remimazolam During Dexmedetomidine Pretreatment
Shanghai Pulmonary Hospital, Shanghai, China
Luscid
Universitair Ziekenhuis Brussel
A Study of APG-1252 in Patients With SCLC or Other Solid Tumors
Ascentage Pharma Group Inc.
APG-1252 in Patients With SCLC or Advanced Solid Tumors
Ascentage Pharma Group Inc.